1.65
+0.04 (+2.48%)
Taking everything into account, LBPS scores 1 out of 10 in our fundamental rating. LBPS was compared to 190 industry peers in the Pharmaceuticals industry. Both the profitability and financial health of LBPS have multiple concerns. LBPS does not seem to be growing, but still is valued expensively.
1. Profitability
1.1 Basic Checks
- LBPS had negative earnings in the past year.
1.2 Ratios
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -125.66% | ||
| ROE | N/A | ||
| ROIC | -55.1% |
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- The Operating Margin and Gross Margin are not available for LBPS so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | -10376.92% | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
- With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), LBPS is destroying value.
- Compared to 1 year ago, LBPS has more shares outstanding
- The debt/assets ratio for LBPS is higher compared to a year ago.
2.2 Solvency
- Based on the Altman-Z score of -8.18, we must say that LBPS is in the distress zone and has some risk of bankruptcy.
- A Debt/Equity ratio of 0.42 indicates that LBPS is not too dependend on debt financing.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.42 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -8.18 |
ROIC/WACC-5.29
WACC10.41%
2.3 Liquidity
- A Current Ratio of 5.21 indicates that LBPS has no problem at all paying its short term obligations.
- LBPS has a Quick Ratio of 5.16. This indicates that LBPS is financially healthy and has no problem in meeting its short term obligations.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 5.21 | ||
| Quick Ratio | 5.16 |
3. Growth
3.1 Past
- The earnings per share for LBPS have decreased strongly by -43.21% in the last year.
- LBPS shows a decrease in Revenue. In the last year, the revenue decreased by -3.70%.
EPS 1Y (TTM)-43.21%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%67.97%
Revenue 1Y (TTM)-3.7%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%11.54%
3.2 Future
- LBPS is expected to show a decrease in Earnings Per Share. In the coming years, the EPS will decrease by -0.36% yearly.
- No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-7.11%
EPS Next 2Y-10.93%
EPS Next 3Y-11.78%
EPS Next 5Y-0.36%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
- No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. Valuation
4.1 Price/Earnings Ratio
- The Price/Earnings Ratio is negative for LBPS. In the last year negative earnings were reported.
- Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for LBPS. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | -0.99 |
4.3 Compensation for Growth
- A cheap valuation may be justified as LBPS's earnings are expected to decrease with -11.78% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-10.93%
EPS Next 3Y-11.78%
5. Dividend
5.1 Amount
- No dividends for LBPS!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
4D Pharma PLC / LBPS FAQ
What is the ChartMill fundamental rating of 4D Pharma PLC (LBPS) stock?
ChartMill assigns a fundamental rating of 1 / 10 to LBPS.
Can you provide the valuation status for 4D Pharma PLC?
ChartMill assigns a valuation rating of 1 / 10 to 4D Pharma PLC (LBPS). This can be considered as Overvalued.
Can you provide the profitability details for 4D Pharma PLC?
4D Pharma PLC (LBPS) has a profitability rating of 0 / 10.
Can you provide the expected EPS growth for LBPS stock?
The Earnings per Share (EPS) of 4D Pharma PLC (LBPS) is expected to decline by -7.11% in the next year.